tetano
Editor, Senior Moderator
Eur J Clin Microbiol Infect Dis
. 2020 Nov 25.
doi: 10.1007/s10096-020-04111-3. Online ahead of print.
COVID-19 IgG/IgM antibody testing in Los Angeles County, California
Khadije Ahmad[SUP] 1 [/SUP], Vahid Rezvanizadeh[SUP] 1 [/SUP], Suraj Dahal[SUP] 1 [/SUP], April Kinninger[SUP] 1 [/SUP], Ahmed K Ghanem[SUP] 1 [/SUP], Suvasini Lakshmanan[SUP] 1 [/SUP], Sajad Hamal[SUP] 1 [/SUP], Ferdinand Flores[SUP] 1 [/SUP], Christopher Dailing[SUP] 1 [/SUP], Sion K Roy[SUP] 1 [/SUP], Matthew J Budoff[SUP] 2 [/SUP]
Affiliations
Abstract
Evidence suggests that asymptomatic and mild SARS-CoV-2 infections comprise > 95% of all cases. Developing a test that indicates past infection and possible immunity against the virus is important. We administered 244 antibody tests to three groups of high-risk population. The test consisted of an IgG component and an IgM component. The overall IgM/IgG positivity for patients with none, mild, moderate, and severe symptoms were 21.1%, 21.8%, 14.2%, and 26.9%, respectively. Those with moderate or severe symptoms were no more or less likely to have positive antibody tests than those with no or mild symptoms.
Keywords: COVID-19; IgG; IgM; antibodies; coronavirus; testing.
. 2020 Nov 25.
doi: 10.1007/s10096-020-04111-3. Online ahead of print.
COVID-19 IgG/IgM antibody testing in Los Angeles County, California
Khadije Ahmad[SUP] 1 [/SUP], Vahid Rezvanizadeh[SUP] 1 [/SUP], Suraj Dahal[SUP] 1 [/SUP], April Kinninger[SUP] 1 [/SUP], Ahmed K Ghanem[SUP] 1 [/SUP], Suvasini Lakshmanan[SUP] 1 [/SUP], Sajad Hamal[SUP] 1 [/SUP], Ferdinand Flores[SUP] 1 [/SUP], Christopher Dailing[SUP] 1 [/SUP], Sion K Roy[SUP] 1 [/SUP], Matthew J Budoff[SUP] 2 [/SUP]
Affiliations
- PMID: 33241444
- DOI: 10.1007/s10096-020-04111-3
Abstract
Evidence suggests that asymptomatic and mild SARS-CoV-2 infections comprise > 95% of all cases. Developing a test that indicates past infection and possible immunity against the virus is important. We administered 244 antibody tests to three groups of high-risk population. The test consisted of an IgG component and an IgM component. The overall IgM/IgG positivity for patients with none, mild, moderate, and severe symptoms were 21.1%, 21.8%, 14.2%, and 26.9%, respectively. Those with moderate or severe symptoms were no more or less likely to have positive antibody tests than those with no or mild symptoms.
Keywords: COVID-19; IgG; IgM; antibodies; coronavirus; testing.